Author:
Rashad Alaa,Nafady Asmaa,Hassan Mohammed H.,Mansour Haggagy,Taya Usama,Bazeed Shamardan Ezzeldin S.,Aref Zaki F.,Sayed Mennatallah Ali Abdelrhman,Nafady-Hego Hanaa,Abdelmaksoud Aida A.
Abstract
AbstractEvidence on the efficacy of adding macrolides (azithromycin or clarithromycin) to the treatment regimen for COVID-19 is limited. We testify whether adding azithromycin or clarithromycin to a standard of care regimen was superior to standard of supportive care alone in patients with mild COVID-19.This randomized trial included three groups of patients with COVID-19. The azithromycin group included, 107 patients who received azithromycin 500 mg/24 h for 7 days, the clarithromycin group included 99 patients who received clarithromycin 500 /12 h for 7 days, and the control group included 99 patients who received standard care only. All three groups received only symptomatic treatment for control of fever and cough .Clinical and biochemical evaluations of the study participants including assessment of the symptoms duration, real-time reverse transcription-polymerase chain reaction (rRT-PCR), C-reactive protein (CRP), serum ferritin, D-dimer, complete blood count (CBC), in addition to non-contrast chest computed tomography (CT), were performed. The overall results revealed significant early improvement of symptoms (fever, dyspnea and cough) in patients treated with either azithromycin or clarithromycin compared to control group, also there was significant early conversion of SARS-CoV-2 PCR to negative in patients treated with either azithromycin or clarithromycin compared to control group (p < 0.05 for all).There was no significant difference in time to improvement of fever, cough, dyspnea, anosmia, gastrointestinal tract "GIT" symptoms and time to PCR negative conversion between patients treated with azithromycin compared to patients treated with clarithromycin (p > 0.05 for all). Follow up chest CT done after 2 weeks of start of treatment showed significant improvement in patients treated with either azithromycin or clarithromycin compared to control group (p < 0.05 for all).Adding Clarithromycin or azithromycin to the therapeutic protocols for COVID-19 could be beneficial for early control of fever and early PCR negative conversion in Mild COVID-19.Trial registration: (NCT04622891) www.ClinicalTrials.gov retrospectively registered (November 10, 2020).
Funder
South valley University, Faculty of Medicine, Qena83523, Egypt.
Publisher
Springer Science and Business Media LLC
Reference40 articles.
1. Amodio, E., Vitale, F., Cimino, L., Casuccio, A. & Tramuto, F. Outbreak of novel coronavirus (SARS-Cov-2): First evidences from International Scientific Literature and Pending Questions. Healthcare (Basel) 8(1), 51 (2020).
2. Mishra, S. Designing of cytotoxic and helper T cell epitope map provides insights into the highly contagious nature of the pandemic novel coronavirus SARS-CoV-2. R Soc. Open Sci. 7(9), 201141 (2020).
3. Aly, M. H. et al. Indicators of critical illness and predictors of mortality in COVID-19 patients. Infect Drug Resist. 13, 1995–2000 (2020).
4. Devaux, C. A., Rolain, J. M., Colson, P. & Raoult, D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?. Int. J. Antimicrob. Agents 55(5), 105938 (2020).
5. Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun [Research Support, Non-U.S. Gov't]. 2004;323(1):264–8.
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献